Table 3.
Clinicopathologic parameters and expression of IGFBP-3 for the prognosis of 70 ESCC patients by univariate survival analysis (log-rank test)
| Variable | All cases | Mean survival (months) | Median survival (months) | P valuea |
|---|---|---|---|---|
| Ageb | 0.739 | |||
| >60 years | 57 | 29.2 | 13.0 | |
| ≤60 years | 13 | 19.0 | 18.0 | |
| Sex | 0.036 | |||
| Male | 45 | 19.4 | 13.0 | |
| Female | 25 | 46.4 | 24.0 | |
| Location | 0.316 | |||
| Cervical | 9 | 31.9 | 19.0 | |
| Thoracic | 61 | 26.8 | 13.0 | |
| Tumor sizec | 0.028 | |||
| >6 cm | 22 | 14.3 | 13.0 | |
| ≤6 cm | 48 | 33.7 | 20.0 | |
| WHO grade | 0.721 | |||
| G1 | 9 | 28.4 | 19.0 | |
| G2 | 29 | 28.0 | 12.0 | |
| G3–4 | 32 | 24.0 | 18.0 | |
| T category | <0.001 | |||
| T1–3 | 50 | 37.0 | 17.0 | |
| T4 | 20 | 16.7 | 12.0 | |
| N category | 0.003 | |||
| N0 | 21 | 32.4 | 18.0 | |
| N1 | 49 | 23.4 | 14.0 | |
| M category | 0.006 | |||
| M0 | 50 | 33.9 | 19.0 | |
| M1-lymd | 20 | 15.1 | 12.0 | |
| Clinical stage | ||||
| II | 19 | 41.8 | 25.0 | 0.067 |
| III | 31 | 25.3 | 13.0 | |
| IV | 20 | 15.1 | 12.0 | |
| IGFBP-3 expression | <0.001 | |||
| High | 32 | 44.6 | 25.0 | |
| Low | 38 | 10.9 | 10.0 | |
WHO World Health Organization
aBy χ2 test
bMean age
cMean tumor size
dDistant lymph node metastasis